Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Conditions

• Aggressive Non-Hodgkin Lymphoma
• Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
• Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma
• Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
• Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma
• Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
• Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma
• Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
• Diffuse Large B-Cell Lymphoma
• High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
• High Grade B-Cell Lymphoma, Not Otherwise Specified
• Indolent Non-Hodgkin Lymphoma
• Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
• Transformed Non-Hodgkin Lymphoma

Interventions

• DRUG: Cyclophosphamide
• DRUG: Doxorubicin Hydrochloride
• DRUG: Etoposide
• BIOLOGICAL: Nivolumab
• DRUG: Prednisone
• BIOLOGICAL: Rituximab
• DRUG: Vincristine Sulfate

Sponsor

David Bond, MD

Collaborators

• [object Object]